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Background: In recent years attention has focused on γH2AX as a very sensitive double strand break indicator. It
has been suggested that γH2AX might be able to predict individual radiosensitivity. Our aim was to study the
induction and repair of DNA double strand breaks labelled by γH2AX in a large cohort.
Methods: In a prospective study lymphocytes of 136 rectal cancer (RC) patients and 59 healthy individuals were
ex vivo irradiated (IR) and initial DNA damage was compared to remaining DNA damage after 2 Gy and 24 hours
repair time and preexisting DNA damage in unirradiated lymphocytes. Lymphocytes were immunostained with
anti-γH2AX antibodies and microscopic images with an extended depth of field were acquired. γH2AX foci counting
was performed using a semi-automatic image analysis software.
Results: Distinct increased values of preexisting and remaining γH2AX foci in the group of RC patients were found
compared to the healthy individuals. Additionally there are clear differences within the groups and there are
outliers in about 12% of the RC patients after ex vivo IR.
Conclusions: The γH2AX assay has the capability to identify a group of outliers which are most probably patients
with increased radiosensitivity having the highest risk of suffering radiotherapy-related late sequelae.
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In radiation therapy there is a need to find a monitoring
assay which can predict a patients’ individual radiosensi-
tivity and the risk to develop early and late tissue reac-
tion and to adjust the radiation dose when indicated. A
pretreatment identification of cancer patients by a pre-
dictive assay of normal-tissue radiosensitivity may allow
appropriate adjustment of treatment and could reduce
the risk of therapy related side effects. Several different
predictive assay strategies were tested, for review see [1].
To monitor the development of DNA double strand
breaks (DSB) γH2AX was established as a well-known
biomarker and over the last years the γH2AX assay has
come into the focus of attention as a predictive assay.
H2AX is a member of the histone H2A family [2].
H2AX is rapidly phosphorylated after exposure of cells* Correspondence: Luitpold.Distel@uk-erlangen.de
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unless otherwise stated.to ionizing radiation. γH2AX phosphorylation develops
in minutes and reaches its maximum after about 30 mi-
nutes [3]. The number of DNA DSBs can be directly de-
termined by the number of foci present in the cell
shortly after DNA damage [4], since it has been proved
that one γH2AX focus represents one DNA DSB [5].
Rothkamm et al. proclaimed that H2AX phosphorylation
and γH2AX foci formation are now generally accepted
as consistent and quantitative markers of DSBs, applic-
able even under conditions where only a few DSBs are
present [5].
The efficiency of γH2AX detection as a biomarker for
DNA DSBs makes this protein a good candidate as a
therapeutic marker for improving the efficiency of radi-
ation, drug and other therapies [6-8]. Dickey et al. re-
vealed that γH2AX is a sensitive indicator of DNA DSBs
and is therefore a potentially useful tool in the detection
of genotoxic stress. Such an indicator could be valuable
in monitoring cancer development and progression as
well as other instances of cell stress. Future work in thisl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Distribution by age and gender for the groups of rectal
cancer patients (RC) and healthy individuals. (A) The whole study
population separated by patients (blue bars) and healthy individuals
(red bars). (B) Patients’ group and (C) healthy individuals group
separated by gender. Female (red bars) and male (blue bars).
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tion assay to the clinic where it will be used as a prac-
tical means to detect cancer and monitor therapeutic
progress [9]. Therefore, the aim of this study was to
evaluate the importance of the γH2AX assay in the de-
tection of rectal cancer patients with remaining γH2AX
foci and a possibly increased radiosensitivity.
Methods
Study participants
The prospective study included a total of 195 individ-
uals. Enrolled were 136 rectal cancer patients (RC) and
59 healthy individuals (Figure 1A). All Patients were
treated with neoadjuvant radiochemotherapy and total
mesorectal excision surgery. Radiotherapy consisted of
50.4 Gy in 28 daily fractions of 1.8 Gy. The patients’ age
was between 23 and 87 years (Figure 1B) with a mean
age of 63.7 years. The age of the control group was
between 27 and 80 (Figure 1C) with a mean age of
56.0 years. Table 1 shows an overview of stage and
radiotherapeutic and chemotherapeutic treatment of all
individuals. This study was approved by the ethics re-
view committees of the Friedrich-Alexander-Universität
Erlangen-Nürnberg (No. 2725) and all patients and
healthy individuals gave their written informed consent.
Blood samples were collected shortly before the first ir-
radiation treatment. Afterwards the patients received a
conventional fractionation schedule of radiation (1.8 Gy/
fraction) up to a total dose of 50.4 Gy.
Immunofluorescence Staining
Patients and healthy individuals’ blood samples were
split into three samples. One sample was used as control
to detect the spontaneous γH2AX foci formation. The
second sample was ex vivo irradiated with 0.5 Gy X-rays
and 30 minutes incubation time and the third one with
2 Gy and 24 hours incubation time. The two different
doses were chosen, because a dose of 2 Gy induces after
30 min such a high number of foci that it is not possible
to count the foci accurately. On the contrary, with a
dose of 0.5 Gy and 24 hours repair the amount of foci is
too low to have sufficient foci numbers. Therefore for
the initial γH2AX foci a low and for the remaining
γH2AX foci after 24 hours repair time a high dose was
chosen. Peripheral blood mononucleated cells (PBMC)
were isolated by Ficoll gradient centrifugation and were
cytocentrifuged (StatspinCytofuge, Kreatech, Germany)
onto a specimen. The samples were fixed with methanol
and acetone and afterwards washed in a phosphate-
buffered saline with foetal calf serum. The slides were
then incubated with a mouse anti-γH2AX antibody
(Abcam, Cambridge, UK), washed in PBS and incubated
with a secondary goat anti-mouse Alexa 488 fluorescent
antibody (Molecular Probes, Karlsruhe, Germany).
Table 1 Healthy individuals and rectal cancer (RC) patients’ characteristics
Number of
individuals









Healthy individuals 59 56.0/58.5
Patients 136 63.7/66.0 0/8.1/75.7/16.2 25.7/64.5/2.9/3.7 89.5/10.5 50.4
Kroeber et al. Radiation Oncology  (2015) 10:36 Page 3 of 7Afterwards lymphocytes were washed in PBS and
mounted with Vectashield mounting medium (Vector
Laboratories, Peterborough, UK).
γH2AX foci recognition
Fluorescence labelled lymphocytes were visualised by a
fluorescence-microscope (Axioplan 2, Zeiss, Göttingen,Figure 2 Immunostained γH2AX foci in lymphocytes 24 h post 2Gy IR
scanning confocal microscope and (B) a resulting combined extended focu
59 healthy individuals (HI, blue) and 136 rectal cancer patients (red).Germany) and image acquisition software (Metafer 4,
MetaSystems, Altlußheim, Germany). Digital images of
five optical planes separated by a distance of 0.75 μm
were recorded and combined to an extended focus
image using the maximum intensity algorithm (Metasys-
tems). An area of 2 mm2 (magnification 630×) was cap-
tured automatically. For each of the samples at least. (A) 30 z-sections with a 0.23 μm step size acquired by a laser
s image. (C) Preexisting, initial and remaining γH2AX foci per cell in
Figure 3 Frequency distribution of the individual γH2AX foci
per cell as measured in ex vivo irradiated lymphocytes after
immunostaining. 59 healthy individuals (blue bars) were compared
to 136 rectal cancer patients (red bars). The data were fitted using a
Gaussian distribution for the (A) preexisting γH2AX foci, (B) initial
γH2AX foci 30 min post IR with 0.5 Gy (C) remaining γH2AX foci
24 h post IR with 2 Gy. Dashed blue vertical lines indicate the value
of two and three standard deviations from the mean of the healthy
individuals and solid red lines the value of two and three standard
deviations from the mean of the RC patients, respectively. (D) Preexisting
γH2AX foci were correlated to remaining γH2AX foci 24 h post IR with
2Gy. HI = healthy individuals, RC = rectal cancer patients.
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software (Biomas, Erlangen, Germany). All DAPI-stained
nuclei were morphologically considered by eye and
apoptotic cells were excluded. Using the image analysis
software the γH2AX foci inside each nucleus were
counted [10]. The number of mean foci per cell was de-
termined for every individual before irradiation, 30 mi-
nutes after 0.5 Gy and 24 h after 2 Gy ionising radiation
(IR). A representative image of γH2AX foci location in
the lymphocytes was acquired by a laser scanning confocal
microscope (LSM710, Zeiss, Göttingen, Germany). 30 z-
sections with a 0.23 μm step size were recorded and com-
bined to an extended focus image (Figure 2A, B).
Statistical analysis
Data analysis and statistics were performed using SPSS
21 for Windows (IBM Corp., Armonk, NY, USA). For
comparing the results referred to the different groups,
the Kolmogorov–Smirnov test and Lilliefors test were
applied for testing normality and data were fitted by a
Gaussian distribution. Standard deviations of the Gauss-
ian distributions have been used to designate an individ-
ual’s categorization. The cut-off values of 2 and 3
standard deviations are equivalent to the 95% and 99%
confidence intervals. Different groups were compared
using the two-sample t-test. Graphics were plotted with
TechPlot for Windows 3.0.11 (SFTek, Dr. Ralf Dittrich,
Braunschweig, Germany).
Results
γH2AX foci rates in a group of 136 RC patients were com-
pared to 59 healthy individuals (Figure 1). Patients’ charac-
teristics are described in Table 1. Three samples per patient
were analysed. Preexisting γH2AX foci were compared to
initial foci numbers exposed to 0.5 Gy IR and a 30 minutes
waiting period. Remaining γH2AX foci were scored after
exposure to 2 Gy IR and 24 hours recovery time.
First it was estimated how many cells had to be
counted to obtain reliable γH2AX rates. The suitable
minimum number to yield stable γH2AX rates was
estimated by a Bland Altman analysis. The agreement
between the γH2AX foci rates after every 200 cells was
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would be 100%. Deviations up- and downward are indi-
cated by higher and lower percentages, respectively. A
deviation of ±15% was defined as the range of tolerance.
Counting 400 unirradiated lymphocytes, the range for
the parameter γH2AX foci rate was very large. When
scoring about 600 lymphocytes, 75% of the values were
within the defined range of tolerance of z or ±15% of the
1000 lymphocytes values. By scoring 800 lymphocytes
95% of the values were within the defined range of toler-
ance of ±15%. Though a minimum number of 600 lym-
phocytes were counted and if it was suitable, about 1000
lymphocytes were scored.
The preexisting γH2AX foci rates in lymphocytes of RC
patients’ were significantly increased compared to the
healthy individuals (p < 0.001). No difference between the
two groups was found in initial γH2AX rates after 0.5 Gy
and 30 minutes incubation time. The residual foci after a
dose of 2 Gy and 24 hours recovery time were significantly
increased in the RC patients group compared to the
healthy individuals (p < 0.001) (Figure 2C). Additionally in
the patients group an increased number of individuals
with distinct higher γH2AX rates was observed. In order
to analyse this effect, γH2AX rates from healthy individ-
uals and patients were classified into suitable divisions of
γH2AX foci per cell and a Gaussian fit was performed.
This approach was used to evaluate individuals that dis-
tinct fell outside the Gaussian distribution and could be
identified as outliers (Figure 3). Using the Kolmogorov–
Smirnov test, the distributions of the patients and healthy
individuals were normally distributed, while the more
stringent Lilliefors test showed normality for all but the
group of preexisting and remaining γH2AX foci of the
healthy individuals. The mean preexisting γH2AX foci of
the RC patients’ distribution was increased by 20.4% com-
pared to the control group (Figure 3A). The mean values
of the normal distributions for the initial DNA damage
were quite similar (Figure 3B), while the mean residual
DNA damage of the RC patients was increased by 13%
(Figure 3C). In the group of RC patients more outliers
were observed compared to the controls (Table 2). If weTable 2 Percentage of healthy individuals and patients outsid
Gaussian distribution
Group Healthy individuals Rectal
Distribution Healthy individuals Rectal
Exposure Preexisting 2 Gy, 24 h Preexi
mean 0.49 2.63 0.59
>1× SD 17.2% 11.9% 21.9%
>2× SD 5.2% 3.4% 14.6%
>3× SD 3.4% 0.0% 5.1%
Group defines the used healthy individuals or patients group. Distribution defines t
distribution to calculate the percentage of patients outside the one to three standaassume a normal distribution, a single value may be con-
sidered as an outlier if it falls outside the two or three
times the standard deviation. Outside the 2 × SD of RC
patients’ Gaussian distribution were exclusively cancer
patients. 6% of the RC patients have increased values in
preexisting and remaining γH2AX foci and 6% have exclu-
sively increased remaining γH2AX foci. 5.8% of the RC
patients and 1.7% of the healthy individuals had solely in-
creased preexisting γH2AX foci (Figure 3D).
Discussion
In this study we compared the preexisting, induced and
residual DNA double strand breaks in lymphocytes de-
rived from 136 RC patients and 59 healthy individuals.
We found distinct increased values of preexisting and
remaining γH2AX foci in the group of RC patients.
There are clear interindividual differences in both
groups and we did find outliers in about 12% of the RC
patients after ex vivo IR. 6% of the RC patients showed
increased numbers of preexisting γH2AX foci. In the
healthy individuals group there was only one individual
(1.7%) with increased preexisting numbers of γH2AX
foci. We could not correlate the measured values with
radiotherapy related late effects because of the short
period since IR exposure of patients. It is therefore diffi-
cult to judge whether the outliers have an increased ra-
diosensitivity and an increased risk of therapy related
late effects. Nevertheless, there is an unambiguous dif-
ference between the patients group having a distinct in-
creased number of outliers compared to the healthy
individuals. We found three different outlier groups
(Figure 3D). One group (n = 8) has solely increased pre-
existing γH2AX foci and no raised values after ex vivo
irradiation. We suggest that in this group the values are
increased due to an elevated exposure of DNA damaging
agents and not to an impaired DNA damage response.
The second group (n = 8) are individuals having in-
creased preexisting γH2AX foci and likewise increased
γH2AX foci after ex vivo irradiation. Here we would
argue that patients have an impaired DNA damage re-
sponse and therefore already raised preexisting γH2AXe of one to three standard deviations from the mean of a
cancer patients Rectal cancer patients
cancer patients Healthy individuals





he used healthy individual’s distribution or the rectal cancer patient’s
rd deviations. Mean is the mean value of the standard deviation.
Kroeber et al. Radiation Oncology  (2015) 10:36 Page 6 of 7foci and as a consequence increased values after ex vivo
irradiation. In the third group (n = 8) solely the residual
DNA DSB values are raised. Here an impaired DNA
damage response may be sufficient to repair the rarely
appearing spontaneous DNA damages, however is not
sufficient to repair the numerous DNA double strand
breaks induced by a dose of 2 Gy. This indicates that the
outliers identified by ex vivo irradiation may have an im-
paired DNA damage response and probably an increased
risk to develop radiotherapy related side effects. It is
postulated that differences in the repair of DNA DSBs
could possibly be related to differences in radiation sen-
sitivity among individuals [11].
Some studies reported an association between γH2AX
foci and individual radiosensitivity. Fleckenstein et al.
found a correlation between a serious mucositis and a
rising number of foci 24 hours after ex vivo irradiation
[12]. Similar Li et al. found that patients with severe oral
mucositis had increased remaining damage 24 h after
ex vivo irradiation compared to patients with mild oral
mucositis [13]. Another study on a breast cancer patients
group with an adverse acute skin reaction (grade 3) to
radiotherapy showed significantly increased radiation-
induced γH2AX foci [14]. Additionally the disappearance
of the foci was delayed compared to the group of breast
cancer patients with normal skin reaction (grade 0–1)
[14]. Another study showed clear differences in DNA re-
pair capacity reflected by γH2AX foci formation in cells
from a high proportion of apparently normal individuals
using a low dose-rate assay [15]. In addition the persist-
ence of γH2AX foci after the induction of DNA damage
suggests that some of the damage remains unrepaired,
which makes γH2AX an attractive candidate for the rapid
assessment of radiation sensitivity in individuals and cell
lines [16]. This may lead to the identification of cell lines
and human subjects with defective DNA repair [17,18].
On the other hand there have been some studies
reporting contradictory results and showing some weak-
ness in the γH2AX assay. One group stated that γH2AX
focus measurement has limited scope as a pre-RT pre-
dictive assay in lymphoblast cell lines from RT patients;
however, the assay can successfully identify DNA DSB
repair-defective patient’s cell lines [19]. Werbrouck et al.
concluded from a gynaecological cancer collective that
scoring γH2AX foci in isolated T lymphocytes after
ex vivo irradiation is not predictive for late radiotoxicity
[20]. The same authors confirmed in another study that
no correlation was found between the γH2AX foci kinet-
ics and the risk for acute normal tissue complications
among patients during IMRT treatment for head and neck
cancer [21]. With these contradictory results, Ivashkevich
et al. suggested further validation of the assay to show
whether the method is specific enough to be predictive in
the identification of radiosensitive patients. They alsosupported the idea that even if the correlation between
the assay and clinical radiosensitivity is incomplete, the
ability of the assay to detect that subset of radiosensitive
patients with defective DNA DSB repair pathways would
be valuable per se [22].
There is much hope that the γH2AX assay has the
capability to predict individual radiosensitivity [11,22].
The analysis of chromosomal aberrations has been
proved to predict individual radiosensitivity. It is another
lymphocyte based assay [23,24] however it takes several
days and is work-intensive. The γH2AX assay can be
performed quickly and can also be readily automated
[22]. Recently, the automatic analyzes of γH2AX foci
was reported [25,26]. Our approach of processing sam-
ples is fairly similar, yet with a lower level of automation.
The main difference may be that in our system the soft-
ware marks cells and foci and the user must finally
accept or reject these selections. Technical problems
with counting foci in the rounded lymphocytes we have
overcome by using focal plane merging [27]. We used
composite images with an extended depth of field con-
sisting of five optical planes.
Conclusions
In conclusion the γH2AX assay has the capability to
identify a group of outliers which are probably patients
with increased radiosensitivity which have the highest
risk suffering from radiotherapy-related late sequelae.
Future follow-up on these patients will correlate ex vivo
data with clinical outcome.
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